Squamous cell carcinoma of the anal canal · line 1 · Carboplatin + paclitaxel (anal carcinoma, metastatic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-CARBO-PACLI-ANAL-MET`

ID	`IND-ANAL-SCC-METASTATIC-1L-CARBO-PACLI`
Type	Indication
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	`DIS-ANAL-SCC`
Sources	`SRC-NCCN-ANAL-2025`

Used By

Algorithms

ALGO-ANAL-SCC-1L - ALGO-ANAL-SCC-1L

Indication

IND-ANAL-SCC-METASTATIC-1L-RETIFANLIMAB-CARBO-PACLI - IND-ANAL-SCC-METASTATIC-1L-RETIFANLIMAB-CARBO-PACLI